JP2023512025A - 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法 - Google Patents

肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法 Download PDF

Info

Publication number
JP2023512025A
JP2023512025A JP2022546019A JP2022546019A JP2023512025A JP 2023512025 A JP2023512025 A JP 2023512025A JP 2022546019 A JP2022546019 A JP 2022546019A JP 2022546019 A JP2022546019 A JP 2022546019A JP 2023512025 A JP2023512025 A JP 2023512025A
Authority
JP
Japan
Prior art keywords
rhodatristat
ethyl
compound
daily dosage
rvt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512025A5 (https=
Inventor
スティーブン エー． リング，
ミシェル パラシオス，
クライザー， ケイトリン ライガード
ビル シモンズ，
ダニエル パターソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altavant Sciences GmbH
Original Assignee
Altavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences GmbH filed Critical Altavant Sciences GmbH
Publication of JP2023512025A publication Critical patent/JP2023512025A/ja
Publication of JP2023512025A5 publication Critical patent/JP2023512025A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022546019A 2020-01-31 2021-01-29 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法 Pending JP2023512025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968651P 2020-01-31 2020-01-31
US62/968,651 2020-01-31
PCT/IB2021/000046 WO2021152398A1 (en) 2020-01-31 2021-01-29 Dosages and methods for treating pulmonary arterial hypertension with rodatristat

Publications (2)

Publication Number Publication Date
JP2023512025A true JP2023512025A (ja) 2023-03-23
JP2023512025A5 JP2023512025A5 (https=) 2024-01-25

Family

ID=75143674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546019A Pending JP2023512025A (ja) 2020-01-31 2021-01-29 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法

Country Status (9)

Country Link
US (1) US20230074252A1 (https=)
EP (1) EP4096633A1 (https=)
JP (1) JP2023512025A (https=)
KR (1) KR20220156813A (https=)
CN (1) CN115379825A (https=)
AU (1) AU2021212355A1 (https=)
CA (1) CA3165432A1 (https=)
MX (1) MX2022009254A (https=)
WO (1) WO2021152398A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413287B2 (en) 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en) * 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530299A (ja) * 2013-09-06 2016-09-29 カロス・ファーマシューティカルズ・インコーポレイテッドＫａｒｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119912A1 (en) * 2018-11-14 2020-05-22 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530299A (ja) * 2013-09-06 2016-09-29 カロス・ファーマシューティカルズ・インコーポレイテッドＫａｒｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
""Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl", NEWS PROVIDED BY ALTAVANT SCIENCES, JPN6024052430, 31 January 2019 (2019-01-31), ISSN: 0005617434 *
ROBERT J. AIELLO ET AL.: ""Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulm", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 360, no. 2, JPN6024052429, 2017, pages 267 - 279, XP055670218, ISSN: 0005617435, DOI: 10.1124/jpet.116.237933 *

Also Published As

Publication number Publication date
WO2021152398A1 (en) 2021-08-05
EP4096633A1 (en) 2022-12-07
AU2021212355A1 (en) 2022-08-18
CN115379825A (zh) 2022-11-22
CA3165432A1 (en) 2021-08-05
MX2022009254A (es) 2022-09-07
KR20220156813A (ko) 2022-11-28
US20230074252A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
US12370195B2 (en) Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
EP2720696B1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
JP2008510830A (ja) ホスホジエステラーゼ５阻害剤（ｐｄｅ５）と併用するエンドセリンａ受容体（ｅｔａ）アンタゴニストおよびその使用
JP2023512025A (ja) 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法
US20190290627A1 (en) Pim kinase inhibitor combinations
AU2016238903A1 (en) Combination of Pl3K inhibitor and c-Met inhibitor
US20210290651A1 (en) Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
EP2753931A1 (en) Autoimmune and inflammatory disorder therapy
JP2016508969A (ja) Ｃｎｋｓｒ１を阻害するための方法及び組成物
TWI722568B (zh) 用於癌症治療之ＴＧＦβ抑制劑及ＣＤＫ抑制劑之組合
JP2023510797A (ja) Ａｈｒ阻害剤及びその使用
WO2009055021A1 (en) Methods and compositions for treating hepatic diseases
EP3241552A1 (en) Compositions and methods for lipid metabolism disorder
Khosravan et al. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects
HK40079142A (en) Dosages and methods for treating pulmonary arterial hypertension with rodatristat
WO2023091625A1 (en) Use of maribavir for the treatment of and treatment regimens thereof
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
Pandey et al. Febuxostat-a new treatment for hyperuricaemia in gout-a review article
WO2024102778A1 (en) Pyrrolopyrimidine compositions for treatment of itk mediated conditions
JP2025523817A (ja) 慢性移植片対宿主病の治療におけるベルモスジル代謝産物及びその使用
Gras Baricitinib. Tyrosine-protein kinase JAK1/JAK2 inhibitor, treatment of rheumatoid arthritis
HK1193045B (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250613